NCT03936933: Pharmacodynamic Study of Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Advanced Breast Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 50 Years (Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with confirmed signs or symptoms related to cerebral metastasis or radiographically-confirmed brain metastasis

Comments are closed.

Up ↑